Morphotek and Centocor Collaborate to Develop High-Titer Antibody Producing Cell Line

Strategic Insights -

Morphotek Inc., a biotechnology company specializing in the development of protein and antibody products, has announced the successful development of a high-titer antibody producing cell line in collaboration with Centocor, Inc. This achievement resulted in an undisclosed milestone payment to Morphotek. The cell line was developed using Morphotek's proprietary MORPHODOMA(R) technology, which rapidly evolves lead mammalian cell lines to generate subclones. The resulting protein products exhibit enhanced therapeutic efficacy and genetically enhanced cells showing high titers of protein for scalable manufacturing.

Key Takeaways:

  • Morphotek's proprietary MORPHODOMA(R) technology was used to develop a high-titer antibody producing cell line in collaboration with Centocor, Inc.
  • The cell line was developed to produce protein products with enhanced therapeutic efficacy and genetically enhanced cells showing high titers of protein for scalable manufacturing.
  • Morphotek received an undisclosed milestone payment as a result of the successful development.
  • Nicholas C. Nicolaides, Ph.D., President and Chief Executive Officer of Morphotek, credited the company's scientific staff and Centocor scientists for their collaborative effort in developing the optimal cell line.
  • Philip M. Sass, Ph.D., Executive Vice President and Chief Operating Officer, highlighted the successful application of Morphotek's platform process for advancing the development of therapeutic proteins and attendant high-titer manufacturing cell lines.
  • Morphotek is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation, and infectious disease.

Statistics:

  • The cell line developed using Morphotek's proprietary technology is expected to yield protein products with enhanced therapeutic efficacy.
  • The genetically enhanced cells exhibit high titers of protein for scalable manufacturing.
  • Morphotek has developed a platform process for advancing the development of therapeutic proteins and attendant high-titer manufacturing cell lines.
  • The company is currently focusing on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation, and infectious disease.

Sources:

  • Exton, Pa., April 6 /PRNewswire/ -- Morphotek Inc. announced today ...
  • Morphotek(R) Inc. is a biotechnology company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology.
  • http://www.morphotek.com/